A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling.

Stanislav Ermolaev,Aleksandr Vasiliev,Aino Skasyrskaya

doi:10.3390/pharmaceutics13060914

Abstract

A new two-column 225Ac/213Bi generator was developed specifically for using 225Ac containing an impurity of long lived 227Ac. The parent 225Ac was retained on the first Actinide Resin column, while 213Bi was accumulated on the second column filled with AG MP-50 resin via continuous elution and decay of intermediate 221Fr. The 213Bi accumulation was realized in circulation mode which allowed a compact generator design. It was demonstrated that 213Bi could be quickly and effectively extracted from AG MP-50 in form of complexes with various chelating agents including DTPA and DOTA. The performance of the generator presented and a conventional single-column generator on the base of AG MP-50 was tested and both generators were loaded with 225Ac containing 227Ac impurity. The 213Bi generation efficiencies were comparable and greater than 70%, whereas the developed generator provided a deeper degree of purification of 213Bi from Ac isotopes and decay products of 227Ac.

Highlights

We report data on capacity factor k’ of Fr(I) onto Actinide Resin in neutral
A new two-column 225 Ac/213 Bi generator intended for using the parent 225 Ac with impurity is proposed and investigated
The formation and concentration of 213 Bi on the second column is realized by continuous separation of intermediate 221 Fr from 225 Ac fixed on the first column

Summary

Introduction

A new two-column 225 Ac/213 Bi generator was developed for using 225 Ac containing an impurity of long lived 227 Ac. The parent 225 Ac was retained on the first Actinide. 70%, whereas the developed generator provided a deeper degree of purification of 213 Bi from Ac isotopes and decay products of 227 Ac. The radionuclide, 213 Bi, is considered as one of the promising radionuclides for targeted therapy of cancer [1,2]. Radiopharmaceuticals containing 213 Bi are successfully passing clinical trials for the treatment of leukemia [3], NHL [4], carcinoma [5], neuroendocrine tumor [6], glioma [7], and melanoma [8].

Methods

Results

Conclusion